期刊
NATURE
卷 533, 期 7604, 页码 547-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nature17954
关键词
-
资金
- Howard Hughes Medical Institute
- Prostate Cancer Foundation
- American Cancer Society [12-038-01-CCE]
- National Cancer Institute [R01CA168899, R01CA172382, R01CA190289, P01 CA163227, P50 CA090381]
- US Army Medical Research and Materiel Command [PC121382]
Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis(1,2). Abiraterone is metabolized in patients to Delta(4)-abiraterone (D4A), which has even greater anti-tumour activity and is structurally similar to endogenous steroidal 5 alpha-reductase substrates, such as testosterone(3). Here, we show that D4A is converted to at least three 5 alpha-reduced and three 5 beta-reduced metabolites in human serum. The initial 5 alpha-reduced metabolite, 3-keto-5 alpha-abiraterone, is present at higher concentrations than D4A in patients with prostate cancer taking abiraterone, and is an androgen receptor agonist, which promotes prostate cancer progression. In a clinical trial of abiraterone alone, followed by abiraterone plus dutasteride (a 5 alpha-reductase inhibitor), 3-keto-5 alpha-abiraterone and downstream metabolites were depleted by the addition of dutasteride, while D4A concentrations rose, showing that dutasteride effectively blocks production of a tumour-promoting metabolite and permits D4A accumulation. Furthermore, dutasteride did not deplete the three 5 beta-reduced metabolites, which were also clinically detectable, demonstrating the specific biochemical effects of pharmacological 5 alpha-reductase inhibition on abiraterone metabolism. Our findings suggest a previously unappreciated and biochemically specific method of clinically fine-tuning abiraterone metabolism to optimize therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据